Jetrea (Ocriplasmin) Approved For Symptomatic Vitreomacular Adhesion In The Eyes, FDA
A new medication, Jetrea (ocriplasmin), has been approved by the FDA for VMA (symptomatic vitreomacular adhesion), an eye condition related to aging that can lead to complications and vision loss. When the vitreous gel adheres too strongly to the retina, it can lead to VMT (vitreomacular traction), which may in the long-run affect vision significantly...